Gritstone Oncology Hauls $93M In Series B Funding

Gritstone Oncology Hauls $93M In Series B Funding

California-based cancer upstart, Gritstone Oncology, has announced successful completion of $92.7 million series B preferred stock financing.

The round was led by new investor Lilly Asia Ventures, with participation from GV, Trinitas Capital and Alexandria Venture Investments, and existing investors Versant Ventures, The Column Group, Clarus Funds and Frazier Healthcare Partners. In conjunction with the funding, Judith Li, partner at Lilly Asia Ventures, will join Gritstone’s board of directors.
Launched in October 2015, the company aims to leverage deep learning to identify and deploy therapeutic neoantigens from individual patients’ tumor to develop novel treatments for lung and gastric cancer.

The next-generation personalized cancer immunotherapy company intends to use the proceeds from the financing to advance its tumor antigen identification platform and pipeline of personalized cancer immunotherapies.
The company’s lead program, targeting tumor-specific neoantigens, is expected to enter clinical trials in mid-2018, initially in patients with non-small cell lung cancer and gastric cancer.
“We are excited to expand our investor base with leading investors from the U.S. and Asia, and to continue driving Gritstone’s best-in-class approach to develop personalized immunotherapies,” said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone

Oncology. “Since the formation of the company two years ago, Gritstone has made significant progress leveraging extensive human tumor molecular analysis and machine learning to develop and optimize the proprietary Gritstone EDGE tumor antigen identification platform. We have matched our breakthrough accuracy in tumor neoantigen identification with an antigen delivery system that builds on human immunity insights from infectious disease experts, culminating in an extremely potent neoantigen delivery platform expected to drive best-in-class cytotoxic T cell responses.”
“Lilly Asia Ventures believes in the potential of targeted immunotherapy to transform the treatment of cancer, and is very actively investing in this domain,” said Judith Li, partner at Lilly Asia Ventures, who will join the board of directors. “Gritstone is building a highly differentiated approach to tailor immunotherapy treatment to each patient’s own tumor, analogous to how tumor gene panel sequencing has enabled application of precisely targeted small molecule targeted therapies to some cancer patients. We believe Gritstone’s global perspective shows exceptional foresight, exemplified by their collection of tumors from Asia to inform antigen prediction in East Asian patients’ tumors. We see top companies increasingly pursuing geographic diversity even in early stages, mirroring the increasingly global nature of biotech innovation.”
“Gritstone is creating a new class of cancer immunotherapies that is revolutionary in its scope and ambition,” said Anthony Philippakis, venture partner at GV. “The company has made meaningful progress applying sophisticated deep learning technologies to create cancer therapeutics that are personalized for each patient. We’re looking forward to working with Gritstone’s experienced team as they continue to make significant steps towards developing a new class of cancer immunotherapies.”